• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cardiovascular Systems Inc. (Amendment)

    2/9/22 3:33:33 PM ET
    $CSII
    Medical/Dental Instruments
    Health Care
    Get the next $CSII alert in real time by email
    SC 13G/A 1 tv0511-cardiovascularsystems.htm SCHEDULE 13G/A cardiovascularsystemsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  Cardiovascular Systems Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  141619106

    Date of Event Which Requires Filing of this Statement: December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  141619106

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    74,709

    7.  SOLE DISPOSITIVE POWER

    2,594,698

    8.  SHARED DISPOSITIVE POWER

    105,680

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,700,378

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.66%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Cardiovascular Systems Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    1225 Old Highway 8 NW
    St. Paul, MN 55112

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    141619106

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2022

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

    Get the next $CSII alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CSII

    DatePrice TargetRatingAnalyst
    12/21/2022$15.00Equal Weight
    Barclays
    12/14/2022$25.00Buy
    Lake Street
    3/2/2022$22.00Underperform
    BofA Securities
    2/4/2022$25.00 → $20.00Outperform
    SVB Leerink
    11/17/2021Buy → Hold
    Needham
    11/10/2021Buy → Neutral
    Guggenheim
    11/10/2021$45.00 → $40.00Outperform
    SVB Leerink
    9/23/2021$50.00 → $49.00Buy
    Needham
    More analyst ratings

    $CSII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Womack Kelvin K.

      4 - Cardiovascular Systems Inc (0001180145) (Issuer)

      4/27/23 4:35:24 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Paulsen Erik

      4 - Cardiovascular Systems Inc (0001180145) (Issuer)

      4/27/23 4:38:00 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Points Jeffrey S.

      4 - Cardiovascular Systems Inc (0001180145) (Issuer)

      4/27/23 4:37:02 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care

    $CSII
    SEC Filings

    See more
    • SEC Form 15-12G filed by Cardiovascular Systems Inc.

      15-12G - Cardiovascular Systems Inc (0001180145) (Filer)

      5/8/23 6:00:37 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Cardiovascular Systems Inc.

      S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)

      5/1/23 6:03:42 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Cardiovascular Systems Inc.

      S-8 POS - Cardiovascular Systems Inc (0001180145) (Filer)

      5/1/23 6:05:14 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care

    $CSII
    Leadership Updates

    Live Leadership Updates

    See more
    • Big Sky Biomedical Appoints Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director

      MINNEAPOLIS, March 7, 2022 /PRNewswire-PRWeb/ -- Big Sky Biomedical, a leading-edge medical device and health technology incubator, announced today that it has appointed Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director. "Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest growing segments of healthcare, including neurovascular, structural heart, and regenerative medicine," said Dr. Egeland. "I'm extremely excited to apply my scientific, medical, and commercial experience to our portfolio companies in a much broader and deeper capacity. Alongside our exceptional teams of engineers, scientists, operators, and physician partners, I loo

      3/7/22 12:00:00 PM ET
      $CSII
      $MDT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D., as Chief Medical Officer

      Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer. "CSI is developing an exciting product pipeline that targets some of the fastest growing segments of interventional cardiology," said Scott Ward, Chairman, President and Chief Executive Officer. "Jeff brings contemporary interventional cardiology practice and extensive clinical research experience to CSI as we seek to expand our product offering beyond orbital atherectomy. We believe Jeff brings valuable per

      3/4/22 7:00:00 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

      CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

      2/9/21 4:01:00 PM ET
      $CSII
      $MEI
      $CNMD
      Medical/Dental Instruments
      Health Care
      Electrical Products
      Technology

    $CSII
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cytek Biosciences Set to Join S&P SmallCap 600

      NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector May 1, 2023 S&P SmallCap 600 Addition Cytek Biosciences CTKB Health Care S&P SmallCap 600 Deletion Cardiovascular Systems CSII Health C

      4/25/23 5:54:00 PM ET
      $ABT
      $CSII
      $CTKB
      $SPGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Laboratory Analytical Instruments
    • Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial

      Largest randomized coronary atherectomy trial ever conducted Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company completed the enrollment of its 2,000 patient ECLIPSE coronary trial. ECLIPSE is a prospective, multi-center, randomized clinical trial of approximately 2,000 subjects with severely calcified coronary lesions in the United States. Half of the participants received orbital atherectomy prior to drug-eluting stent implantation, while the other half received conventional angioplasty, including speci

      4/3/23 4:05:00 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

      Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin

      2/8/23 6:12:00 PM ET
      $ABT
      $CSII
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $CSII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on Cardiovascular Systems with a new price target

      Barclays initiated coverage of Cardiovascular Systems with a rating of Equal Weight and set a new price target of $15.00

      12/21/22 7:41:39 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Cardiovascular Systems with a new price target

      Lake Street initiated coverage of Cardiovascular Systems with a rating of Buy and set a new price target of $25.00

      12/14/22 9:03:31 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • BofA Securities resumed coverage on Cardiovascular Systems with a new price target

      BofA Securities resumed coverage of Cardiovascular Systems with a rating of Underperform and set a new price target of $22.00

      3/2/22 7:23:56 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care

    $CSII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Cardiovascular Systems Inc. (Amendment)

      SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)

      2/13/24 3:24:48 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Cardiovascular Systems Inc. (Amendment)

      SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)

      2/14/23 9:00:06 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Cardiovascular Systems Inc. (Amendment)

      SC 13G/A - Cardiovascular Systems Inc (0001180145) (Subject)

      2/13/23 1:26:27 PM ET
      $CSII
      Medical/Dental Instruments
      Health Care

    $CSII
    Financials

    Live finance-specific insights

    See more
    • Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

      Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin

      2/8/23 6:12:00 PM ET
      $ABT
      $CSII
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Cardiovascular Systems, Inc. to Host Earnings Conference Call on February 9, 2023

      Cardiovascular Systems, Inc. (NASDAQ:CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results. Click here to access the live webcast. A replay will be available later the same day. Click here to register for the conference call. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic pla

      1/19/23 7:00:00 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care
    • Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results

      Conference Call Scheduled for Today, November 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET)  Revenues of $59.7 million increased 2.2% compared to first quarter last year Management reiterates fiscal 23 revenue guidance of $255 million to $265 million, representing 8% to 12% growth Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its first quarter, ended September 30, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO "We are pleased with the state of our business and our perfor

      11/3/22 7:00:00 AM ET
      $CSII
      Medical/Dental Instruments
      Health Care